Prime Medicine, Inc. (PRME) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Prime Medicine reported revenue of $4.6M, up 55.3% from $3.0M the year before. Net income was -$201.1M (a -4342.4% net margin), or -$1.35 per diluted share. Operating margin was -4498.1%. Operating activities generated -$162.6M of cash, leaving -$167.1M of free cash flow. At fiscal year end, Prime Medicine held $342.7M in total assets against $221.9M in total liabilities, including $63.0M of cash and equivalents.
Open the full interactive Prime Medicine financials → Quarterly statements, key ratios, valuation history and price charts.
Prime Medicine Key Stats
| Share Price | $3.32 |
|---|---|
| Market Cap | $588.4M |
| Revenue YoY Growth | +55.3% |
| 52-Week Range | $2.70 – $6.37 |
| Shares Outstanding | 177.2 million (basic, 2026 Q2) |
Prime Medicine Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $3.0M | $4.6M |
| Operating Income | -$116.5M | -$204.8M | -$202.5M | -$208.3M |
| Pre-Tax Income | -$122.8M | -$198.4M | -$195.9M | -$201.1M |
| Income Tax | -$948,000 | -$279,000 | $0 | $0 |
| Net Income | -$121.8M | -$198.1M | -$195.9M | -$201.1M |
| Diluted EPS | -$4.19 | -$2.18 | -$1.65 | -$1.35 |
Prime Medicine Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $1.2M | $838,000 | $0 | $0 |
| Net Income | -$50.6M | -$46.1M | -$49.1M | -$42.1M |
| Diluted EPS | -$0.32 | -$0.31 | -$0.28 | -$0.24 |
Prime Medicine Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $187.6M | $41.6M | $182.5M | $63.0M |
| Current Assets | $296.6M | $143.0M | $211.9M | $181.3M |
| Total Assets | $360.3M | $193.9M | $297.5M | $342.7M |
| Current Liabilities | $26.7M | $56.4M | $38.0M | $37.4M |
| Total Liabilities | $44.0M | $60.8M | $144.4M | $221.9M |
| Shareholders' Equity | $316.3M | $133.1M | $153.1M | $120.9M |
Prime Medicine Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$131.8M | -$165.4M | -$122.9M | -$162.6M |
| Cash From Investing | -$47.1M | $18.7M | $68.5M | -$108.8M |
| Cash From Financing | $181.5M | $655,000 | $195.9M | $151.5M |
| Free Cash Flow | -$147.9M | -$174.1M | -$130.2M | -$167.1M |
Figures from Prime Medicine's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Prime Medicine financials page for every line item.
Prime Medicine Company Profile
| Ticker | PRME |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001894562 |
Frequently Asked Questions
What was Prime Medicine's revenue in fiscal 2025?
Prime Medicine (PRME) reported revenue of $4.6M for fiscal 2025.
What is Prime Medicine's annual revenue history?
Prime Medicine's annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $3.0M; 2025: $4.6M.
What was Prime Medicine's net income in fiscal 2025?
Prime Medicine reported net income of -$201.1M for fiscal 2025.
What was Prime Medicine's earnings per share (EPS) in fiscal 2025?
Prime Medicine's diluted EPS was -$1.35 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Prime Medicine generate in fiscal 2025?
Prime Medicine generated -$167.1M of free cash flow in fiscal 2025.
What was Prime Medicine's revenue last quarter?
In its most recent reported quarter (2026 Q2), Prime Medicine reported revenue of $0.
How many shares of Prime Medicine are outstanding?
Prime Medicine reported a weighted average of 177.2 million basic shares outstanding in 2026 Q2.
What is Prime Medicine's market cap?
Based on its latest closing price, Prime Medicine (PRME) has a market capitalization of about $588.4M.
When does Prime Medicine's fiscal year end?
Prime Medicine's fiscal year end, as registered with the SEC, is December 31.
Where is Prime Medicine headquartered?
Prime Medicine lists its business address in Cambridge, Massachusetts in its SEC filings.
Prime Medicine Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →